Acro Biomedical (ACBM) Net Cash Flow (2016 - 2025)
Acro Biomedical (ACBM) has 10 years of Net Cash Flow data on record, last reported at -$225.0 in Q4 2025.
- For Q4 2025, Net Cash Flow changed 0.0% year-over-year to -$225.0; the TTM value through Dec 2025 reached $3622.0, up 3522.0%, while the annual FY2025 figure was $3622.0, 3522.0% up from the prior year.
- Net Cash Flow reached -$225.0 in Q4 2025 per ACBM's latest filing, down from $4297.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $262420.0 in Q1 2022 and bottomed at -$345561.0 in Q2 2022.
- Average Net Cash Flow over 5 years is -$701.25, with a median of -$225.0 recorded in 2024.
- Peak YoY movement for Net Cash Flow: plummeted 26936.0% in 2021, then skyrocketed 4108.15% in 2022.
- A 5-year view of Net Cash Flow shows it stood at -$59415.0 in 2021, then skyrocketed by 82.6% to -$10336.0 in 2022, then soared by 71.99% to -$2895.0 in 2023, then skyrocketed by 92.23% to -$225.0 in 2024, then changed by 0.0% to -$225.0 in 2025.
- Per Business Quant database, its latest 3 readings for Net Cash Flow were -$225.0 in Q4 2025, $4297.0 in Q3 2025, and -$225.0 in Q2 2025.